Environmental safety assessment of vaccines derived from biotechnology.
Products derived from biotechnology are generally safer than previous products obtained by conventional, more empirical methods. Given the great variety of biotechnology-derived products and use situations, risk assessment procedures must be based on a case-by-case analysis. It is therefore difficult to propose a generic, well-defined risk assessment procedure. In the case of vectored vaccines, two main risks must clearly be assessed: the possible risk of tissue or species tropism modification, with special regard to non-target species, the risk of recombination with wild counterparts of the vector. This paper begins with a classification and description of the main biotechnology-derived products to be used in veterinary medicine, including deoxyribonucleic acid (DNA) vaccines, and then attempts to define general rules for the risk assessment of each category of products.
Pastoret
P P
PP
Department of Immunology and Vaccinology, Faculty of Veterinary Medicine, University of Liège, Sart Tilman, Belgium.
Brochier
B
B
Denis
M
M
D000818:Animals; D000835:Animals, Wild; D001709:Biotechnology; D005818:Genetic Engineering; D006564:Herpesviridae / Q000276:immunology; D006801:Humans; D011819:Rabies Vaccines / Q000592:standards; D018570:Risk Assessment; D012449:Safety; D014614:Vaccines, Synthetic / Q000592:standards*; D014765:Viral Vaccines / Q000592:standards
D011819:Rabies Vaccines; D014614:Vaccines, Synthetic; D014765:Viral Vaccines